Entity
  • Asceneuron SA

    Created in 2012
  • BETA

    Up & running (A)
    Existing signals show a regular activity
  • Social networks

    2,855
  • Activities

  • Technologies

  • Entity types

  • Location

    1015 Lausanne, Switzerland

    Lausanne

    Switzerland

  • Employees

    Scale: 2-10

    Estimated: 20

  • Engaged corporates

    3
    2 2
  • Added in Motherbase

    3 months, 1 week ago
Description
  • Value proposition

    Targeting the root cause of neurodegeneration

    Asceneuron is a clinical stage biotech company focused on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need. The pipeline reflects our ambition to develop treatments for a wide a range of neurodegenerative diseases including orphan tauopathies, Alzheimer’s and Parkinson’s disease. Asceneuron has two clinical stage small molecule O-GlcNAcase inhibitors in development for the treatment of proteinopathies including Parkinson’s Disease, Alzheimer’s disease and related disorders.

    Asceneuron is a privately held company financed by a renowned syndicate of investors consisting of Sofinnova Partners, M Ventures, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and Kurma Partners. For more information, please visit www.asceneuron.com.


    Further information: www.asceneuron.com


    Orphan Diseases, Tauopathies, Alzheimer's disease, Small Molecule Drug Discovery, Neurodegeneration, Novel Therapeutics, PSP, Parkinson's disease, and Biotechnology

Corporate interactions BETA
Corporate TypeTweets Articles
Sofinnova Partners
Sofinnova Partners
Financial Services
Sofinnova Partners
Financial Services
Other

21 Jul 2024


GSK
GSK
Pharmaceutical, Pharmaceutical Manufacturing
GSK
Pharmaceutical, Pharmaceutical Manufacturing
Other

21 Jul 2024


EPFL Innovation Park
EPFL Innovation Park
Startup accelerator & VC, Professional Training and Coaching
EPFL Innovation Park
Startup accelerator & VC, Professional Training and Coaching
Other

19 Jul 2024


Similar entities
Loading...
Loading...
Social network dynamics